Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
TOKYO, April 14, 2013
TOKYO, April 14, 2013 /PRNewswire/ --Astellas Pharma Inc. ("Astellas"; Tokyo:
4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of
Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas'
Headquarters for the Americas in Northbrook, Illinois, USA and will report to
Sef Kurstjens, M.D., Ph.D., newly named Chief Medical Officer at Astellas. In
April 2013, Astellas established the Chief Medical Officer position in order
to further integrate and enhance Astellas' delivery of global medical
Astellas President and CEO Yoshihiko Hatanaka said, "I am pleased that Dr. Xue
will be joining us at Astellas as head of Global Pharmacovigilance. Dr. Xue's
knowledge and experience will help the company pursue its operational
excellence and further enhance our global PV and product compliance
With Dr. Xue's appointment, Astellas has now completed the hiring of global
heads in the areas of PV, Medical Affairs, Regulatory Affairs, Clinical and
Research Quality Assurance, and Quality Assurance.
During his more than twenty years in the pharmaceutical industry, Dr. Xue has
held increasingly senior roles with global responsibilities in drug safety and
pharmacoepidemiology. Most recently, Dr. Xue held the position of Senior Vice
President, Head Global Pharmacovigilance at Takeda Pharmaceuticals, Inc. Prior
to joining Takeda, Dr. Xue held posts with global pharmaceutical companies
such as Novartis and Wyeth.
Dr. Xue received his medical degree from Shanxi Medical College in Shanxi
China. Subsequently, he received a Masters of Science (clinical epidemiology)
degree fromHunan University of Medical Science, Hunan, China, and a Doctor of
Philosophy degree (Ph.D.) in epidemiology from the University of Minnesota.
About Astellas Pharma Inc.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. Astellas has
approximately 17,000 employees worldwide. The organization is committed to
becoming a global category leader in Urology, Immunology (including
Transplantation) and Infectious Diseases, Oncology, Neuroscience and DM
Complications and Kidney Diseases. For more information on Astellas Pharma
Inc., please visit the company website at www.astellas.com/en.
SOURCE Astellas Pharma Inc.
Contact: Jenny Kite, Astellas, 224-205-5405
Press spacebar to pause and continue. Press esc to stop.